We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers.
- Authors
Pue, M. A.; Pratt, S. K.; Fairless, A. J.; Fowles, S.; Laroche, J.; Georgiou, P.; Prince, W.
- Abstract
Twenty healthy male volunteers received single oral doses of famciclovir (125–750 mg), in a randomized, single-blind, crossover study. Plasma and urine concentrations of penciclovir and its 6-deoxy precursor, BRL 42359, were determined and penciclovir plasma concentration-time data submitted to model-independent pharmacokinetic analysis. Peak plasma concentrations of penciclovir were obtained at median times of 0.5–0.75 h after dosing. The areas under the concentration versus time curves (AUC) and the peak penciclovir concentration (C) increased linearly with dose of famciclovir. Time to C, elimination half-life, urinary recovery and renal clearance of penciclovir did not change with increasing dose. Famciclovir was excreted via the kidneys as penciclovir (60%) and BRL 42359 (5%), respectively. Famciclovir was well tolerated by all subjects with a low incidence of adverse effects. In conclusion, penciclovir thus displays linear pharmacokinetics in the anticipated therapeutic dose range of famciclovir.
- Subjects
ACYCLOVIR; ANTIVIRAL agents; COMPARATIVE studies; HIGH performance liquid chromatography; RESEARCH methodology; MEDICAL cooperation; ORAL drug administration; PRODRUGS; PURINES; RESEARCH; SPECTROPHOTOMETRY; TIME; EVALUATION research; RANDOMIZED controlled trials; BLIND experiment
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 1994, Vol 33, Issue 1, p119
- ISSN
0305-7453
- Publication type
journal article